Overnight Market report, page-1133

Is that so? i thought we only had mPFS. Can you point me to where i can find the final PFS for first line NSCLC total expanded cohort?

If you've been following closely the results of early cohorts of Tacti-mel, tacti-002 and Insight-004 you would of noticed gradual improvements overtime in ORR. so late responders is not uncommon, its been noted in some of Immuteps web presentations. Potential theory for this is that as EFTI causes a sustained improvement in immune response via increase in cd8 t cells, NK, etc, and decrease in t cell exhaustion, overtime the immune system in some patients is able to gain the upper hand on the cancer. This observation is not observed in prembo monotherapy.

i personally think we are too early for OS/Biomarker data. but what do i know, you may be right...